Connect with us


Italian biotech companies entered the race to find a vaccine against COVID-19

Several Italian biotech companies, such as Irbim, ReiThera and Takis, have entered the international race to develop a vaccine that would end the coronavirus outbreak. Researchers are also working around the clock to discover the best test kit to identify people infected with COVID-19 and stop the spreading of the pandemic. DiaSorin developed a test that can identify even mutations of the virus.



This picture show a person receiving a vaccine.

A group of Italian biotech companies has recently entered the world race to contain and finally defeat the coronavirus, and are getting results. While the chronicles are full of Japanese miracle drugs and vaccine trials in the four corners of the world, Italian biotech is getting international recognition and is close to important trials.

“Perhaps more than other sectors, we are aware of what it means to face a pandemic,” said Riccardo Palmisano, president of Assobiotec-Federchimica, the trade association that brings together over 130 companies involved in biotechnology and pharmaceuticals (as well as agriculture and the environment). “For this reason, like the entire productive fabric, we have taken measures against the virus, we have done smart working and readjusted shifts, but the laboratories have never remained empty because at the end of our chain there is the patient, not only those affected by the coronavirus,” Palmisano continued.

For more information about the latest breakthrough in the biotech sector, install our companion app Born2invest. Read the most important financial headlines and be the first to find out when a vaccine against COVID-19 will be available.

Italian researchers are working hard to find a vaccine

Palmisano explained that there are several centers of excellence in the territory equipped to make a contribution against the virus, especially in two fields: diagnostics and vaccines.

In the field of testing, there is DiaSorin, a company based near Vercelli. With a very strong international presence, the company has developed a molecular diagnostic test capable of giving results on coronavirus positivity within an hour. The test is so sensitive that it is able to recognize the virus even in case of mutations.

The U.S. division of the company, DiaSorin Molecular, was one of the few companies to receive emergency approval from the U.S. Food and Drug Administration to proceed with the use of its tests, along with some federal funds. DiaSorin tests are carried out with machines that the company has already installed all over the world.

Irbm, ReiThera and Takis are among the companies that have entered the race to find a vaccine against COVID-19

Three Italian companies have also entered the vaccine race, and all three come from Lazio, where a pole of excellence has been created in recent years.

Irbm is a company that counts over 250 scientists and has entered in collaboration with the Jenner Institute of the University of Oxford to create a vaccine against the new coronavirus. Irbm has a lot of experience since back in 2016 the company developed a vaccine against Ebola. In addition, in recent years, Irbm has already done a lot of work on another parainfluenza virus, the adenovirus. Irbm has started the development of the first batch of vaccines for clinical trials (i.e. those on people), which hopes to start before the summer.

ReiThera was also involved in the development of a vaccine to stop Ebola. The company’s vaccine against the coronavirus is currently being tested in vitro and on animals. The company should have a 10,000-dose batch ready to begin clinical trials by the end of May.

Similar timing for Takis, a biotech company that has developed four possible variants of the vaccine. The company started animal testing in collaboration with the Spallanzani Institute. The first results should arrive by the end of April, and clinical trials will take place by the end of the year.

“Italy has many scientists of international excellence and we should not need a global pandemic to remind us of that,” said Palmisano. “We have the weapons to fight this emergency and defeat it, but there are ways to be better prepared when the next one comes.”

Palmisano recalled that research funding is not yet at the European level: “The target for 2020 would have been to allocate 3% of GDP to research, but we are still at 1.3. And this is why when this crisis is over we need a national plan: Italy has all the capacity to be a protagonist.”


(Featured image by TheDigitalArtist via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in IL FOGLIO, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Olivia McCall is passionate about education, women and children’s rights, and the environment. A long-time investor, she covers news about the latest stocks (lately marijuana and tech), IPOs and indices, and is always on the lookout for socially responsible startups. She also writes about the food sector, and has a keen interest on cryptocurrencies.